The HER2 targeting ADC trastuzumab emtansine in combination with pertuzumab has been shown to be as effective as neoadjuvant chemotherapy in HER2 + breast cancer and was associated with a reduced toxicity profile [111–113]. This evidence concerns the gene ERBB2 and breast carcinoma.